Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise
beta
Latest Financials
Filings:
By Category
By Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
Company Exhibits:
Indentures
Material Contracts & Credit Agreements
Plans of Reorganization
Articles and Bylaws
Underwriting Agreements
SEC Edgar
Warby Parker Inc.
SIC 3851 · Ophthalmic Goods
Notes
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Warby Parker Inc.
SIC 3851 · Ophthalmic Goods
Notes
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Warby Parker Inc.
SIC 3851 · Ophthalmic Goods
Notes
Support
about
terms
$
WRBY
Warby Parker Inc.
CIK:
0001504776
|
SEC Filings
Income Statement
Cash Flow
Balance Sheet
v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]
Net revenue
$ 235,511
$ 214,475
$ 477,958
$ 438,257
Cost of goods sold
99,054
100,866
210,460
198,668
Gross profit
136,457
113,609
267,498
239,589
Selling, general, and administrative expenses
133,290
118,134
262,664
241,643
Income (loss) from operations
3,167
(4,525)
4,834
(2,054)
Interest and other income, net
2,084
1,984
4,415
4,439
Income (loss) before income taxes
5,251
(2,541)
9,249
2,385
Provision for income taxes
607
(789)
1,428
665
Net income (loss)
$ 4,644
$ (1,752)
$ 7,821
$ 1,720
Net loss per share attributable to common stockholders, basic (in dollars per share)
$ 0.04
$ (0.01)
$ 0.06
$ 0.01
Net loss per share attributable to common stockholders, diluted (in dollars per share)
$ 0.04
$ (0.01)
$ 0.06
$ 0.01
Weighted average shares used in computing net loss per share attributable to common stockholders, basic
123,935,000
122,565,000
123,688,000
122,257,000
Weighted average shares used in computing net loss per share attributable to common stockholders, diluted
125,748,000
122,565,000
125,680,000
125,719,000
Other comprehensive income (loss)
Foreign currency translation adjustment
$ (26)
$ 170
$ (351)
$ 179
Total comprehensive income (loss)
$ 4,618
$ (1,582)
$ 7,470
$ 1,899
v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities
Net income (loss)
$ 7,821
$ 1,720
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
27,838
24,648
Stock-based compensation
21,295
21,229
Non-cash charitable donations
3,950
2,821
Asset, Impairment Loss
631
486
Amortization of cloud-based software implementation costs
2,064
1,488
Change in operating assets and liabilities:
Accounts receivable, net
1,205
809
Inventory
2,409
9,077
Prepaid expenses and other assets
(20,940)
1,085
Accounts payable
6,710
1,846
Accrued expenses
10,864
10,752
Deferred revenue
(11,295)
(10,836)
Lease assets and liabilities
2,334
4,067
Other liabilities
(757)
365
Net cash provided by operating activities
54,129
69,557
Cash flows from investing activities
Purchases of property and equipment
(39,001)
(32,438)
Net cash used in investing activities
(39,001)
(32,438)
Cash flows from financing activities
Proceeds from stock option exercises
773
117
Shares withheld for taxes on stock-based compensation
(10,604)
(6,361)
Proceeds from shares issued in connection with employee stock purchase plan
1,370
1,169
Net cash used in financing activities
(8,461)
(5,075)
Effect of exchange rates on cash
(351)
179
Net change in cash and cash equivalents
6,316
32,223
Cash and cash equivalents, beginning of period
286,358
254,161
Cash and cash equivalents, end of period
292,674
286,384
Supplemental disclosures
Cash paid for income taxes
1,793
643
Cash paid for interest
162
176
Non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses
$ 8,978
$ 4,645
v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Current assets:
Cash and cash equivalents
$ 292,674
$ 286,358
Accounts receivable, net
2,080
3,285
Inventory
42,104
44,512
Prepaid expenses and other current assets
33,982
18,283
Total current assets
370,840
352,438
Property and equipment, net
201,808
187,448
Right-of-use lease assets
186,302
170,805
Other assets
13,365
10,228
Total assets
772,315
720,919
Current liabilities:
Accounts payable
41,269
31,979
Accrued expenses
61,296
49,225
Deferred revenue
22,574
33,869
Current lease liabilities
35,541
31,399
Other current liabilities
2,800
3,658
Total current liabilities
163,480
150,130
Non-current lease liabilities
215,438
201,749
Other liabilities
1,412
1,310
Total liabilities
380,330
353,189
Commitments and contingencies (see Note 10)
Stockholders’ equity:
Common stock, $0.0001 par value; Class A: 750,000 shares authorized at June 30, 2026 and December 31, 2025, 107,726 and 106,318 issued and outstanding at June 30, 2026 and December 31, 2025, respectively; Class B: 150,000 shares authorized at June 30, 2026 and December 31, 2025, 15,700 and 16,130 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively, convertible to Class A on a one-to-one basis
12
12
Additional paid-in capital
1,071,564
1,054,779
Accumulated deficit
(677,759)
(685,580)
Accumulated other comprehensive loss
(1,832)
(1,481)
Total stockholders’ equity
391,985
367,730
Total liabilities and stockholders’ equity
$ 772,315
$ 720,919